BPC-157 (Body Protection Compound 157): Research Profile and Study Landscape

What BPC-157 is

BPC-157, also referred to as Body Protection Compound 157 or PL 14736, is described in the literature as a synthetic pentadecapeptide — a chain of fifteen amino acids — corresponding to a sequence originally isolated from human gastric juice. Reviews characterise it as a stable gastric peptide that has been investigated across a range of preclinical injury and inflammation models. It has not been approved for standard medical use by the FDA or other regulatory authorities, and reviews attribute this to the absence of sufficient clinical studies in humans.

How the research studies it

In the indexed literature, BPC-157 has been studied in tissue repair, inflammation, gut, tendon and muscle research, predominantly in preclinical (in vitro and animal) models.

What the strongest research examines

In rodent musculoskeletal models, systematic and narrative reviews report that BPC-157 has been associated with markers of angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Mechanistic work cited in these reviews describes engagement of overlapping signaling pathways, including VEGFR2, nitric oxide synthesis via the Akt–eNOS axis, and ERK1/2, in the context of endothelial and muscle repair.

In a rat model of lower-extremity ischemia-reperfusion injury, administration of BPC-157 was associated with lower histopathological renal changes — including vascular and glomerular vacuolization, tubular dilation, hyaline casts, and tubular cell shedding — in analyses of distant organ tissues (kidney, liver, and lung). Broader synthesis reviews describe pleiotropic effects across preclinical models of tissue injury, inflammatory bowel disease, and CNS disorders, and characterise the reported safety profile as favorable with few side effects noted following administration. All of these findings are drawn from animal and in vitro systems or reviews thereof; the reviews uniformly state that comprehensive human clinical data are lacking.

What the research does not show

The human evidence identified in this search is limited in scale; larger controlled trials establishing exposure and long-term safety in humans are not yet available.